Format

Send to

Choose Destination
Int J Infect Dis. 2019 Mar;80S:S23-S28. doi: 10.1016/j.ijid.2019.02.006. Epub 2019 Feb 15.

The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world?

Author information

1
Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK. Electronic address: i.honeyborne@ucl.ac.uk.
2
University College London (UCL) Respiratory, Division of Medicine, UCL, London, UK; Royal Free Hospital London National Health Service Foundation Trust, London, UK. Electronic address: marclipman@nhs.net.
3
Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK; UCL Hospitals and National Institute of Health Research Biomedical Research Centre at UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: a.zumla@ucl.ac.uk.
4
Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK. Electronic address: t.mchugh@ucl.ac.uk.

KEYWORDS:

Clinical trials; Drug resistance; MDR-TB; Treatment regimens; Tuberculosis; XDR-TB

PMID:
30776547
DOI:
10.1016/j.ijid.2019.02.006
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center